Clinical trials: Hearing Loss, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Hearing Loss
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Retinitis Pigmentosa (RP), Usher Syndrome Type 2
Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
The purpose of this Phase 2 Open-label study is to evaluate the long-term safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in participants with Retinitis Pigmentosa due to mutations in exon 13…
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- CAPELLA (NCT07796646)
- Testing
- No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen
- Volunteers
- 81 people
- Sponsor
- Laboratoires Thea
Osteogenesis Imperfecta
Audio-vestibular Evaluation of Children and Young Adults With Osteogenesis Imperfecta
The aim is to determine whether vestibular deficits are present in OI, then to establish whether a correlation exists between genetic type, severity of OI and audiovestibular phenotype.
- Trial name
- AVOI (NCT05419960)
- Testing
- Vestibular Assessment, Petrous bone Computed Tomography (CT), Magnetic Resonance Imaging (MRI)
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Sudden Hearing Loss
Efficacy and Safety of Intracochlear Injection of Glucocorticoid Through the Round Window Membrane in Patients With Profound or Complete Sudden Sensorineural Hearing Loss
Safety and efficacy of intracochlear injection of glucocorticoid through the round window membrane in patients with profound or complete sudden sensorineural hearing loss
- Trial name
- NCT07814677
- Testing
- intracochlear injection of triamcinolone acetonide through the round window membrane, intratympanic dexamethasone injection through the tympanic membrane
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Sudden Sensorineural Hearing Loss (SSNHL)
Intratympanic Injection of Dexamethasone With Hyaluronic Acid in Treatment of Sudden Sensorineural Hearing Loss
To evaluate efficacy of intratympanic injection of dexamethasone and hyaluronic acid mixture as a treatment modality in cases of sudden sensorineural hearing loss (SSNHL).
- Trial name
- NCT06878599
- Testing
- Hyaluronic Acid (HA), Dexamethasone
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Sudden Deafness, Sensorineural Hearing Loss
Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness
Sudden deafness is a common emergency in otorhinolaryngology. As the etiology and mechanism of sudden deafness remains unknown, there is no specific treatment.
- Trial name
- NCT06707389
- Testing
- autologous blood monocyte vesicles (lower dose), Methylprednisolone, autologous blood monocyte vesicles (higher dose)
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Childhood Medulloblastoma
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain.
- Trial name
- NCT05382338
- Testing
- Audiometric Test, Auditory Brainstem Response, Biospecimen Collection
- Where
- 111 sites in United States, Canada
- Volunteers
- 225 people
- Sponsor
- Children's Oncology Group
Ototoxicity, Drug-Induced
Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin
The goal of this clinical trial is to test the effectiveness of the study drug, ORC-13361, in preventing hearing loss in patients with NTM infection who are undergoing treatment with IV amikacin therapy.
- Trial name
- NCT05730283
- Testing
- ORC-13661
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Kevin Winthrop
Solid Tumor Malignancies, Testicular Cancer
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
The purpose of this study is to assess the safety and effectiveness of a drug called Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy.
- Conditions
- Solid Tumor Malignancies, Testicular Cancer, Head and Neck Cancer, Thoracic Cancer
- Trial name
- NCT07407582
- Testing
- Pedmark® STS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Arizona
Sudden Hearing Loss
Effectiveness of Integrative Medical Treatment in Sudden Hearing Loss
Sudden hearing loss is an emergency in otolaryngology that requires diagnosis and treatment as soon as possible. The golden treatment period is two weeks since the onset of the disease.
- Trial name
- NCT07235488
- Testing
- Acupuncture, steroid therapy
- Where
- Taiwan
- Volunteers
- 64 people
- Sponsor
- China Medical University Hospital
Sudden Sensorineural Hearing Loss (SSNHL)
Intracochlear Injection of Glucocorticoid
This study is a prospective, randomized pilot study. To verify safety and efficacy of intracochlear injection of glucocorticoid through the round window membrane in patients with total sudden sensorineural hearing loss safety and…
- Trial name
- NCT07134075
- Testing
- intracochlear triamcinolone acetonide injection, intracochlear injection of dexamethasone through the round window membrane, intracochlear dexamethasone injection and intratympanic dexamethasone injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations
This study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic…
- Trial name
- NCT07288580
- Testing
- EHT102 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Euhearing Therapeutics Co., Ltd
Sudden Hearing Loss, Extracellular Vesicles
Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss
The goal of this clinical trial is to learn if small extracellular vesicles derived from mesenchymal stem cells work to treat severe and above sudden sensorineural hearing loss.
- Trial name
- NCT07404709
- Testing
- Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at low doses, Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at moderate doses, Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at high doses
- Where
- 5 sites in China
- Volunteers
- 9 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Ototoxic Hearing Loss
Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy
One common side effect of cisplatin chemotherapy is ototoxicity. The drugs sodium thiosulfate and mannitol may protect against cisplatin-induced hearing loss.
- Trial name
- NCT05129748
- Testing
- Sodium Thiosulfate + Mannitol
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- Sunnybrook Health Sciences Centre
Sudden Sensorineural Hearing Loss
Effect of Aspirin and Folic Acid for Sudden Sensorineural Hearing Loss
The annual incidence of sudden sensorineural hearing loss (SSNHL) is 5 to 20 per 100 000 persons. The pathophysiology of SSNHL and acute vestibulo-cochlear syndromes (VCS) is unknown in more than 70% of cases.
- Trial name
- SERORL (NCT07113158)
- Testing
- Aspirin + Acid folic
- Where
- France
- Volunteers
- 142 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mitochondrial Disorders, Mitochondrial Genetic Disorders
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.
- Conditions
- Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes
- Trial name
- NAMDC (NCT01694940)
- Where
- 17 sites in United States, Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Sudden Hearing Loss
Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss
Sudden sensorineural hearing loss (SSNHL) is diagnosed when there's a sudden drop in hearing of at least 30 decibels across three consecutive frequencies, emerging within up to 72 hours.
- Trial name
- NCT06467526
- Testing
- Hydroxychloroquine, Steroid
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Chang Gung Memorial Hospital
Sudden Sensorineural Hearing Loss (SSNHL), Prediabetes / Type 2 Diabetes
CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial
This exploratory randomized controlled trial evaluates whether a CGM-guided temporary patch pump (CareLevo CSII) reduces glucocorticoid-induced hyperglycemia (GIH) compared to a Lantus-based basal-bolus injection (MDI) regimen in…
- Trial name
- SHIP (NCT07652528)
- Testing
- CareLevo Patch-type Insulin Pump, Insulin Glargine U-100 (Lantus), Fast-acting Insulin Aspart (Fiasp)
- Volunteers
- 50 people
- Sponsor
- Hallym University
Sudden Sensorineural Hearing Loss (SSNHL)
Autologous Circulating Extracellular Vesicles for Total-Type Sudden Sensorineural Hearing Loss
Total-type sudden sensorineural hearing loss (defined in this study as severe-to-profound sudden sensorineural hearing loss with pure-tone average (PTA) >70 dB HL) represents one of the poorer-prognosis subtypes of sudden…
- Trial name
- NCT07878559
- Testing
- autologous circulating extracellular vesicles, Glucocorticoids
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cisplatin-related Hearing Loss
Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial
The goal of this clinical trial is to learn if transtympanic sodium thiosulfate (STS) injections can prevent hearing loss caused by cisplatin chemotherapy in adults with head and neck cancer.
- Trial name
- SOUND (NCT07281508)
- Testing
- Transtympanic sodium thiosulphate (STS) 0.1M/0,5% hyaluronate
- Where
- 5 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute